Eryilmaz, ErtugrulCanpolat, Cengiz2023-02-212023-02-212017-01-0110.2147/OTT.S126368https://hdl.handle.net/11443/1308http://dx.doi.org/10.2147/OTT.S126368Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15\% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.acute lymphoblastic leukemiaacute myeloid leukemiapediatric leukemiasystemic therapiesArticleWOS:000404879500001